Experimental drug duo targets Hard-to-Treat cancers

NCT ID NCT02595931

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 36 times

Summary

This early-phase trial tests a new drug called M6620 (berzosertib) combined with the chemotherapy irinotecan in people with advanced solid tumors that have spread or can't be removed. The goal is to find the safest dose and see if the combination can slow tumor growth. About 66 participants with cancers like colorectal, pancreatic, or small cell lung cancer are being studied.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Keck Medical Center of USC Pasadena

Pasadena, California, 91105, United States
Los Angeles General Medical Center

Los Angeles, California, 90033, United States
Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States
Siteman Cancer Center at Christian Hospital

St Louis, Missouri, 63136, United States
Siteman Cancer Center at Saint Peters Hospital

City of Saint Peters, Missouri, 63376, United States
Siteman Cancer Center at West County Hospital

Creve Coeur, Missouri, 63141, United States
Siteman Cancer Center-South County

St Louis, Missouri, 63129, United States
Smilow Cancer Center/Yale-New Haven Hospital

New Haven, Connecticut, 06510, United States
Stanford Cancer Institute Palo Alto

Palo Alto, California, 94304, United States
UCSF Medical Center-Mount Zion

San Francisco, California, 94115, United States
UF Health Cancer Institute - Gainesville

Gainesville, Florida, 32610, United States
UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27599, United States
USC / Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States
University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States
University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232, United States
Vanderbilt Breast Center at One Hundred Oaks

Nashville, Tennessee, 37204, United States
Vanderbilt University/Ingram Cancer Center

Nashville, Tennessee, 37232, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States
Wayne State University/Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Yale University

New Haven, Connecticut, 06520, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

M6620 (berzosertib) combined with irinotecan

What this could lead to

If successful, this could point toward a new treatment option for advanced solid tumors that have stopped responding to standard therapies.

What could go wrong

This is an early Phase 1 trial with only 66 participants, focused on safety and dosing. It is too small and early to know if the combination will work or be widely useful.

Conditions

The condition(s) this trial relates to.

cancer colorectal neoplasm exocrine pancreatic carcinoma lung neoplasm malignant pancreatic neoplasm Neoplasm Metastasis pancreatic neoplasm small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.